All Stories

  1. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  2. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  3. Women’s perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting
  4. Tracking children's immune responses reveals an antibody blueprint for fighting malaria
  5. Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria
  6. Evaluation of whole blood CD64 for identifying infection in neonates receiving hospital care
  7. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  8. Development of high affinity antibodies to Plasmodium falciparum merozoite and sporozoite antigens during infancy and adulthood
  9. Role of malaria exposure and off-target responses on RTS,S/AS02A vaccine immunogenicity and protection in Mozambican children
  10. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections
  11. Plasmodium falciparum reticulocyte-binding homologues are targets of human inhibitory antibodies and play a role in immune evasion
  12. Antibody correlates of risk of clinical malaria in an area of low and unstable malaria transmission in western Kenya
  13. Functionally Distinct pTfh1 Subsets with Roles in Malaria-Specific Immunity
  14. Antimicrobials for Neonates: Practitioner Decisions and Diagnostic Certainty
  15. Detrimental infant and maternal outcomes of undiagnosed asymptomatic malaria in pregnancy
  16. IgM Is Prominent and Activates Complement in Acquired Transmission-Blocking Immunity Against Malaria
  17. Women's Perspectives on Health Service Integration Inform Strategies to Address Multi-Morbidity in Pregnancy, Childbirth and Postpartum in a High Burden Setting
  18. Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
  19. Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
  20. Integrated Approaches for the Delivery of Maternal and Child Health Services with Childhood Immunization Programs in Low- and Middle-Income Countries: Systematic Review Update 2011–2020
  21. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  22. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial
  23. Mycoplasma genitalium in pregnancy, including specific co-infections, is associated with lower birthweight: A prospective cohort study
  24. A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
  25. IgM plays a prominent role in naturally acquired immunity against Plasmodium falciparum gametocytes
  26. Geospatial joint modeling of vector and parasite serology to microstratify malaria transmission
  27. Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate
  28. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  29. Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children
  30. A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies
  31. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  32. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  33. Clinical and immunological outcomes of HIV-exposed uninfected and HIV-unexposed uninfected children in the first 24 months of life in Western Kenya
  34. Complement detection on trophozoite stage Plasmodium falciparumparasites using flow cytometry or Western blot
  35. Plasmodium falciparum Growth or Invasion Inhibition Assays
  36. Antibody-dependent cell-mediated cytotoxicity (ADCC) assay with natural killer cells in malaria immunity
  37. Complement-fixation by antibodies to Plasmodium falciparum
  38. Isolation of viable Plasmodium falciparum merozoites
  39. Phagocytosis of antigen-coated beads or malaria parasites using neutrophils
  40. Quantifying antibody binding to Fcγ-receptors in malaria immunity
  41. Acquisition of complement fixing antibodies targeting Plasmodium falciparum merozoites in infants and their mothers in Uganda
  42. A step forward for Plasmodium falciparum malaria transmission-blocking vaccines
  43. Fc-dependent functional activity of ChAdOx1-S and CoronaVac vaccine-induced antibodies to the SARS-CoV-2 spike protein
  44. Associations between prenatal malaria exposure, maternal antibodies at birth, and malaria susceptibility during the first year of life in Burkina Faso
  45. Community perspectives and experiences of quality maternal and newborn care in East New Britain, Papua New Guinea
  46. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  47. Quantifying differences in iron deficiency-attributable anemia during pregnancy and postpartum
  48. Clinical and Immunological Outcomes of HIV-Exposed Uninfected and HIV-Unexposed Uninfected Children in the First 24 Months of Life in Western Kenya
  49. Antibody to Plasmodium falciparum Variant Surface Antigens, var Gene Transcription, and ABO Blood Group in Children With Severe or Uncomplicated Malaria
  50. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis
  51. Defining species-specific and conserved interactions of apical membrane protein 1 during erythrocyte invasion in malaria to inform multi-species vaccines
  52. Low knowledge of newborn danger signs among pregnant women in Papua New Guinea and implications for health seeking behaviour in early infancy – findings from a longitudinal study
  53. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  54. The direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway
  55. Targeting malaria parasites with novel derivatives of azithromycin
  56. The RTS,S malaria vaccine: Current impact and foundation for the future
  57. Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region
  58. Impact of Environmental Modifications on the Ecology, Epidemiology, and Pathogenesis of Plasmodium falciparum and Plasmodium vivax Malaria in East Africa
  59. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  60. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes
  61. Assessment of IgG3 as a serological exposure marker for Plasmodium vivax in areas with moderate–high malaria transmission intensity
  62. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  63. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  64. Antibody dynamics in children with first or repeat Plasmodium falciparum infections
  65. Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children
  66. Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
  67. Quality newborn care in East New Britain, Papua New Guinea: measuring early newborn care practices and identifying opportunities for improvement
  68. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  69. The Plasmodium falciparum parasitophorous vacuole protein P113 interacts with the parasite protein export machinery and maintains normal vacuole architecture
  70. Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
  71. Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women
  72. Partnership-defined quality approach to companionship during labour and birth in East New Britain, Papua New Guinea: A mixed-methods study
  73. Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children
  74. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children.
  75. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children
  76. Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity
  77. Multi-functional antibody profiling for malaria vaccine development and evaluation
  78. Recent clinical trials inform the future for malaria vaccines
  79. Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  80. High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women
  81. Reduced risk of placental parasitaemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  82. Community-based molecular and serological surveillance of subclinical malaria in Myanmar
  83. HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women
  84. Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites
  85. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice
  86. Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection
  87. Mycoplasma genitalium and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015–2017
  88. Complement Factors in COVID-19 Therapeutics and Vaccines
  89. Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity
  90. Risk factors and knowledge associated with high unintended pregnancy rates and low family planning use among pregnant women in Papua New Guinea
  91. RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial
  92. Novel virus-like particle vaccine encoding the circumsporozoite protein ofPlasmodium falciparumis immunogenic and induces functional antibody responses
  93. Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection
  94. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  95. Structure‐Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity
  96. Epitope masking may limit antibody boosting to malaria vaccines
  97. Improving the quality of maternal and newborn care in the Pacific region: A scoping review
  98. Retargeting azithromycin analogues to have dual-modality antimalarial activity
  99. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  100. Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial
  101. Identifying and combating the impacts of COVID-19 on malaria
  102. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  103. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  104. Impact of a rapid decline in malaria transmission on antimalarial IgG subclasses and avidity
  105. Iron Deficiency Is Associated With Reduced Levels of Plasmodium falciparum-specific Antibodies in African Children
  106. Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  107. High burden ofMycoplasma genitaliumand other reproductive tract infections among pregnant women in Papua New Guinea
  108. Th2-like T-follicular helper cells promote functional antibody production duringPlasmodium falciparuminfection
  109. Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination
  110. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  111. Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial
  112. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services
  113. Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial
  114. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services.
  115. Complement in malaria immunity and vaccines
  116. Novel particles for malaria vaccines
  117. IgM in human immunity to Plasmodium falciparum malaria
  118. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
  119. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M
  120. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study
  121. Iron deficiency, malaria, and low birth weight.
  122. Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture
  123. Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
  124. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity
  125. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced inHansenula polymorpha
  126. Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
  127. Dendritic Cell Responses and Function in Malaria
  128. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein
  129. The salt between the beans: a qualitative study of the role of auxiliary midwives in a hard-to-reach area of Myanmar
  130. Understanding how the RTS,S malaria vaccine works
  131. Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection
  132. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination
  133. Targeting malaria parasite invasion of red blood cells as an antimalarial strategy
  134. Targets of complement-fixing antibodies in protective immunity against malaria
  135. Different Life Cycle Stages of Plasmodium falciparum Induce Contrasting Responses in Dendritic Cells
  136. The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children
  137. Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections
  138. Understanding transmission-blocking immunity compared to clinical immunity in malaria
  139. Challenges and strategies for developing efficacious and long-lasting malaria vaccines
  140. KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization
  141. Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol
  142. Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia
  143. Acquisition of Antibodies Against Endothelial Protein C Receptor–Binding Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 in Children with Severe Malaria
  144. Multiple morbidities in pregnancy: Time for research, innovation, and action
  145. Iron deficiency in pregnancy and poor birth outcomes
  146. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial
  147. Cellular dissection of malaria parasite invasion of human erythrocytes using viable Plasmodium knowlesi merozoites
  148. Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time
  149. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
  150. The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization withPlasmodium falciparumMalaria Sporozoites
  151. Mechanism of immunity to malaria - blocking sporozoite infection
  152. Overcoming antigenic diversity of malaria vaccine candidates for better protection
  153. Proteome-wide mapping of immune features onto Plasmodium protein three-dimensional structures
  154. Combating low birth weight due to malaria infection in pregnancy.
  155. Effect of nutrient supplementation on the acquisition of humoral immunity to Plasmodium falciparum in young Malawian children
  156. Establishment of a yeast-based VLP platform for antigen presentation
  157. Antibodies generated by a vaccine against malaria in pregnancy
  158. The potential of task shifting selected maternal interventions to auxiliary midwives in Myanmar: a mixed-method study
  159. Immunity to severe malaria in children
  160. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya
  161. Functional Conservation of the AMA1 Host-Cell Invasion Ligand Between P. falciparum and P. vivax: A Novel Platform to Accelerate Vaccine and Drug Development
  162. Impaired placental autophagy in placental malaria
  163. P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission
  164. Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
  165. Understanding how immunity to malaria develops in children
  166. Identifying new drugs against malaria
  167. Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion
  168. The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum
  169. Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study
  170. Dichotomous miR expression and immune responses following primary blood-stage malaria
  171. Impact of declining malaria transmission on human immunity
  172. The exported chaperone Hsp70-x supports virulence functions for Plasmodium falciparum blood stage parasites
  173. Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates
  174. Determinants of knowledge of critical danger signs, safe childbirth and immediate newborn care practices among auxiliary midwives: a cross sectional survey in Myanmar
  175. Prevention of postpartum haemorrhage by community-based auxiliary midwives in hard-to-reach areas of Myanmar: a qualitative inquiry into acceptability and feasibility of task shifting
  176. Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum
  177. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort
  178. The potential benefit of scaling up malaria prevention to reduce low birth weight in Africa
  179. Plasmodium vivax vaccine research – we’ve only just begun
  180. Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight
  181. Truncated Latrunculins as Actin Inhibitors Targeting Plasmodium falciparum Motility and Host Cell Invasion
  182. Evaluating Complement-Mediated Humoral Immunity to P. falciparum Blood Stages
  183. Differing rates of antibody acquisition in malaria: implications for immunity and surveillance
  184. Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation
  185. Functional Antibodies and Protection against Blood-stage Malaria
  186. A malaria vaccine in children with HIV
  187. Structure–Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1–RON2 Interaction
  188. A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens
  189. Specific antibodies to the PfRH5 invasion complex and protection from malaria
  190. Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period
  191. The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact
  192. Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite
  193. A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies
  194. Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity
  195. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2
  196. Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting
  197. Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
  198. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
  199. Immunity to malaria in an era of declining malaria transmission
  200. High resolution FTIR imaging provides automated discrimination and detection of single malaria parasite infected erythrocytes on glass
  201. Designing malaria vaccines to circumvent antigen variability
  202. Erratum to: CD14 hi CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  203. Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions
  204. Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya
  205. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
  206. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities
  207. Malaria eradication and elimination: views on how to translate a vision into reality
  208. Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum
  209. CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  210. Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens
  211. Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection AgainstPlasmodium falciparumMalaria in Children
  212. The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial
  213. Maximizing antimalarial efficacy and the importance of dosing strategies
  214. Plasmodium vivax Malaria
  215. Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea
  216. Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2
  217. Malaria and immunity during pregnancy and postpartum: a tale of two species
  218. Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria
  219. PfRH5 as a candidate vaccine for Plasmodium falciparum malaria
  220. Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response
  221. Research priorities for the development and implementation of serological tools for malaria surveillance
  222. Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines
  223. Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis
  224. Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1
  225. PTEX is an essential nexus for protein export in malaria parasites
  226. Opsonic phagocytosis of Plasmodium falciparummerozoites: mechanism in human immunity and a correlate of protection against malaria
  227. Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women
  228. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates
  229. A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors
  230. Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria
  231. Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1
  232. Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum
  233. Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines
  234. Antibodies to Polymorphic Invasion-Inhibitory and Non-Inhibitory Epitopes of Plasmodium falciparum Apical Membrane Antigen 1 in Human Malaria
  235. Erythrocyte-Binding Antigens ofPlasmodium falciparumAre Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity
  236. Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development
  237. Acquired Antibodies to Merozoite Antigens in Children from Uganda with Uncomplicated or Severe Plasmodium falciparum Malaria
  238. Reply to Eisenhut
  239. PfEMP1 as a target of human immunity and a vaccine candidate against malaria
  240. Does Malaria Affect Placental Development? Evidence from In Vitro Models
  241. Defining the Timing of Action of Antimalarial Drugs against Plasmodium falciparum
  242. New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology
  243. Platelet Factor 4 and Duffy Antigen Required for Platelet Killing of Plasmodium falciparum
  244. Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria
  245. Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy
  246. The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria
  247. Antigenic Characterization of an Intrinsically Unstructured Protein, Plasmodium falciparum Merozoite Surface Protein 2
  248. New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women
  249. Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity
  250. Malaria Parasite Signal Peptide Peptidase is an ER‐Resident Protease Required for Growth but not for Invasion
  251. Plasmodium vivax Adherence to Placental Glycosaminoglycans
  252. Perspectives: The missing pieces
  253. Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial
  254. High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria
  255. Antibody to P. falciparum in Pregnancy Varies with Intermittent Preventive Treatment Regime and Bed Net Use
  256. Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans
  257. A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
  258. Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen
  259. IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine
  260. Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates
  261. Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery
  262. Placental Malaria-Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation
  263. Super-Resolution Dissection of Coordinated Events during Malaria Parasite Invasion of the Human Erythrocyte
  264. Reticulocyte and Erythrocyte Binding-Like Proteins Function Cooperatively in Invasion of Human Erythrocytes by Malaria Parasites
  265. Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum Malaria
  266. Stepwise dissection of Plasmodium falciparum merozoite invasion of the human erythrocyte
  267. Association between Naturally Acquired Antibodies to Erythrocyte‐Binding Antigens ofPlasmodium falciparumand Protection from Malaria and High‐Density Parasitemia
  268. Minimal Association of Common Red Blood Cell Polymorphisms with Plasmodium falciparum Infection and Uncomplicated Malaria in Papua New Guinean School Children
  269. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand
  270. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development
  271. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites
  272. Using an Improved Phagocytosis Assay to Evaluate the Effect of HIV on Specific Antibodies to Pregnancy-Associated Malaria
  273. Antibodies to Chondroitin Sulfate A–Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment
  274. Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental Plasmodium falciparum-Infected Erythrocytes
  275. Evaluation of the Antigenic Diversity of Placenta-Binding Plasmodium falciparum Variants and the Antibody Repertoire among Pregnant Women
  276. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis
  277. Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays
  278. Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous Plasmodium vivax Strains in Papua New Guinean Children
  279. The future for blood‐stage vaccines against malaria
  280. Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical Plasmodium falciparum Malaria in Children from Papua New Guinea
  281. Sir2 Paralogues Cooperate to Regulate Virulence Genes and Antigenic Variation in Plasmodium falciparum
  282. Antibodies to Reticulocyte Binding Protein-Like Homologue 4 Inhibit Invasion of Plasmodium falciparum into Human Erythrocytes
  283. Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum
  284. Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness
  285. Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum
  286. Recent insights into humoral and cellular immune responses against malaria
  287. Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum
  288. Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults
  289. Exported Proteins Required for Virulence and Rigidity of Plasmodium falciparum-Infected Human Erythrocytes
  290. Estimating the Burden of Global Mortality in Children Aged <5 Years by Pathogen‐Specific Causes
  291. Characteristics of Plasmodium falciparum-Infected-Erythrocyte Adhesion to Chondroitin Sulfate
  292. Polymorphic and Conserved Targets of Antibodies againstPlasmodium falciparumduring Pregnancy
  293. Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development
  294. Quantification of penicillin G during labor and delivery by capillary electrophoresis
  295. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies
  296. Characterization of VAR2CSA-deficient Plasmodium falciparum-infected erythrocytes selected for adhesion to the BeWo placental cell line
  297. Towards a Vaccine against Plasmodium vivax Malaria
  298. Structural Basis for Binding of Plasmodium falciparum Erythrocyte Membrane Protein 1 to Chondroitin Sulfate and Placental Tissue and the Influence of Protein Polymorphisms on Binding Specificity
  299. Serum Lipoproteins Promote Efficient Presentation of the Malaria Virulence Protein PfEMP1 at the Erythrocyte Surface
  300. Antibodies among Men and Children to Placental-Binding Plasmodium falciparum-Infected Erythrocytes that Express var2csa
  301. THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN
  302. Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum–infected erythrocyte surface
  303. Development and Optimization of High-Throughput Methods To Measure Plasmodium falciparum-Specific Growth Inhibitory Antibodies
  304. Antigenic Differences and Conservation among PlacentalPlasmodium falciparum–Infected Erythrocytes and Acquisition of Variant‐Specific and Cross‐Reactive Antibodies
  305. A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria
  306. Promising Functional Readouts of Immunity in a Blood-Stage Malaria Vaccine Trial
  307. Targets of Protective Antibodies to Malaria during Pregnancy
  308. Placental Malaria Induces Variant-Specific Antibodies of the Cytophilic Subtypes Immunoglobulin G1 (IgG1) and IgG3 That Correlate with Adhesion Inhibitory Activity
  309. Cross-Reactive Surface Epitopes on Chondroitin Sulfate A-Adherent Plasmodium falciparum-Infected Erythrocytes Are Associated with Transcription of var2csa
  310. Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype
  311. The Immunology and Pathogenesis of Malaria During Pregnancy
  312. Clinical features and pathogenesis of severe malaria
  313. Variable intrauterine pressure catheter (IUPC)tracings with two catheters
  314. Malaria in pregnancy and the endemicity spectrum: what can we learn?
  315. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection
  316. Phenotypes of Plasmodium falciparum from the Peripheral Blood of Pregnant Women
  317. Antibodies to Variant Surface Antigens ofPlasmodium falciparum–Infected Erythrocytes and Adhesion Inhibitory Antibodies Are Associated with Placental Malaria and Have Overlapping and Distinct Targets
  318. Plasmodium falciparum–Infected Erythrocytes Demonstrate Dual Specificity for Adhesion to Hyaluronic Acid and Chondroitin Sulfate A and Have Distinct Adhesive Properties
  319. An alternative agglutination assay to measure antibodies to variant surfaceantigens of Plasmodium falciparum-infected erythrocytes
  320. Selective Accumulation of Mature Asexual Stages of Plasmodium falciparum-Infected Erythrocytes in the Placenta
  321. Evaluating specific adhesion of Plasmodium falciparum-infected erythrocytes to immobilised hyaluronic acid with comparison to binding of mammalian cells
  322. The Structural Motif in Chondroitin Sulfate for Adhesion ofPlasmodium falciparum-infected Erythrocytes Comprises Disaccharide Units of 4-O-Sulfated and Non-sulfated N-Acetylgalactosamine Linked to Glucuronic Acid
  323. Expanding the paradigms of placental malaria
  324. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation
  325. Parasite adhesion and immune evasion in placental malaria
  326. Sticky rings: challenging the cytoadherence dogma
  327. New agents to combat malaria
  328. Inhibition of Adhesion of Plasmodium falciparum-Infected Erythrocytes by Structurally Defined Hyaluronic Acid Dodecasaccharides
  329. Identification of Glycosaminoglycan Binding Domains in Plasmodium falciparum Erythrocyte Membrane Protein 1 of a Chondroitin Sulfate A-Adherent Parasite
  330. Plasmodium falciparum Rosette Formation Is Uncommon in Isolates from Pregnant Women
  331. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria
  332. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  333. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  334. Plasmodium falciparumIsolates from Infected Pregnant Women and Children Are Associated with Distinct Adhesive and Antigenic Properties
  335. The adhesion ofPlasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated byP. falciparumerythrocyte membrane protein 1
  336. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
  337. Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A
  338. Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain
  339. Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies
  340. Synthesis and transacylating reactivity of β-cyclodextrin ethylenediamines